Breakthrough Molecular Detection Platform Delivers Best-In-Class Accuracy without Need for Target Amplification

A disruptive new platform that operates with a combination of unprecedented speed and accuracy promises to revolutionize molecular detection and emerge as a new gold standard tool to empower clinical decision-making.

VedaBio (San Diego, CA, USA) has harnessed the immense potential of CRISPR technology to create CRISPR Cascade, a game-changing platform that's the outcome of integrating engineering and biology. The CRISPR Cascade eliminates the requirement for target amplification yet offers the same level of accuracy as PCR tests, delivering analytical results in less than a minute. Unlike traditional DNA/RNA amplification methods like PCR, where increasing the complexity of the assay by multiplexing complicates things, CRISPR Cascade eliminates these constraints. It allows for extremely simple, highly multiplexed tests without sacrificing signal quality or encountering cross-reactivity. The platform offers a blend of high sensitivity, precision, and nearly immediate results, opening up a wide range of new possibilities.

One of the standout features of the CRISPR Cascade is its unprecedented speed and processing power, which facilitate almost instant results best-in-class accuracy. This is made possible by the use of two specific ribonucleoproteins (RNPs): the first, known as RNP1, identifies the target genetic sequence, while the second, RNP2, carries out an additional function, like signal amplification, for example. In contrast to existing DNA amplification methods like PCR, where combining multiple primers can reduce the assay's sensitivity and specificity, CRISPR Cascade can pool different RNP1s, allowing for massive multiplexing without any loss in signal-to-noise ratio (SNR) or cross-reactivity issues. This means that creating new tests or target applications becomes a matter of simple RNP1 adjustments. These modifications are compatible with various types of reporting mechanisms, including fluorescence and colorimetric methods. Thanks to its robust, room-temperature chemistry that is highly compatible with microfluidics, CRISPR Cascade enables almost immediate molecular detection along with significant multiplexing capabilities.

“With the CRISPR Cascade reaction, we have unlocked the true power of CRISPR with a platform that delivers near-instant molecular detection of highly multiplexed analytes with best-in-class accuracy, all without the need for target amplification,” said Anurup Ganguli, PhD, Co-Founder and Chief Executive Officer of VedaBio. “We believe it is poised to emerge as a future gold standard for molecular detection, empowering major advances across multiple applications including research and industrial tools, diagnostics and therapeutics.”

Related Links:
VedaBio 

Visit expo >

New

Gold Member

Rickettsia Conorii Assay

RICKETTSIA CONORII ELISA

Antipsychotic TDM Assays
Saladax Antipsychotic Assays

New

Drug Detection Platform

ABSOLUDY Drug Detection Platform

New

Neuron-Specific Enolase ELISA

Human NSE ELISA Test Kit